Among people with Graves' disease, most choose antithyroid drugs first because they fear radiation from radioactive iodine or complications from surgery, while fewer choose surgery or radioactive iodine despite their potential benefits.
Claim Context
Among patients with Graves' disease, 64% prefer antithyroid drugs as their initial treatment, 25% prefer surgery, and 11% prefer radioactive iodine therapy, primarily due to concerns about radioactivity and surgical complications, indicating that treatment choice is strongly influenced by perceived risks rather than clinical efficacy data.
“Antithyroid drugs (ATD) was the most preferred initial treatment (64%), followed by surgery (25%) and radioactive iodine therapy (RAI) (11%), with concerns about radioactivity and surgical complications influencing decisions.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review of randomized trials comparing long-term outcomes (e.g., remission, recurrence, quality of life) across ATD, surgery, and RAI would determine whether patient preferences align with clinical effectiveness.
A systematic review and meta-analysis of all randomized controlled trials comparing antithyroid drugs, thyroidectomy, and radioactive iodine therapy in adults aged 18–70 with newly diagnosed Graves' disease, measuring primary outcomes including euthyroidism at 1 year, recurrence rate, hypothyroidism incidence, quality of life (SF-36), and adverse events over 5 years, with subgroup analysis by age, sex, and presence of ophthalmopathy.
An RCT comparing ATD, surgery, and RAI would determine which treatment leads to higher rates of sustained remission, fewer complications, or better quality of life, independent of patient preference.
A multicenter, double-blind, randomized controlled trial enrolling 600 adults aged 20–65 with newly diagnosed Graves' disease, assigning them to ATD (methimazole 10–30 mg/day for 18 months), total thyroidectomy, or radioactive iodine (15 mCi), with primary outcomes of euthyroidism at 12 months, recurrence by 5 years, and disease-specific quality of life (GRACE scale), and secondary outcomes of hypothyroidism, ophthalmopathy progression, and patient-reported satisfaction.
A prospective cohort study could determine whether patients who choose ATD versus RAI have different long-term outcomes (e.g., recurrence, hypothyroidism, quality of life) after adjusting for baseline characteristics.
A prospective cohort study following 1,000 adults with Graves' disease over 5 years, stratified by initial treatment choice (ATD, surgery, RAI), measuring thyroid function, recurrence, development of hypothyroidism, quality of life (ThyPRO), and adverse events, with multivariable adjustment for age, sex, GO status, socioeconomic status, and baseline anxiety levels.
A cross-sectional survey could quantify the prevalence of specific fears (e.g., radioactivity, scarring) among patients with Graves' disease and correlate them with treatment choice at a single point in time.
A nationwide cross-sectional survey of 2,000 adults diagnosed with Graves' disease within the past 5 years, using validated instruments to measure fear of radiation, surgical complications, and medication side effects, and asking which treatment they selected and why, with stratification by region, education, and access to endocrinology care.
Case reports could document rare but impactful patient experiences (e.g., severe radiophobia leading to treatment refusal) that inform clinical communication strategies.
A case series of 50 patients with Graves' disease who refused recommended radioactive iodine therapy due to extreme fear of radiation, documenting their psychological history, decision-making process, alternative treatments chosen, and long-term outcomes including disease control and mental health impact.